JP2004533421A5 - - Google Patents

Download PDF

Info

Publication number
JP2004533421A5
JP2004533421A5 JP2002574998A JP2002574998A JP2004533421A5 JP 2004533421 A5 JP2004533421 A5 JP 2004533421A5 JP 2002574998 A JP2002574998 A JP 2002574998A JP 2002574998 A JP2002574998 A JP 2002574998A JP 2004533421 A5 JP2004533421 A5 JP 2004533421A5
Authority
JP
Japan
Prior art keywords
monolipopeptide
peptide
composition according
amino acids
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002574998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004533421A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2002/002188 external-priority patent/WO2002076485A2/en
Publication of JP2004533421A publication Critical patent/JP2004533421A/ja
Publication of JP2004533421A5 publication Critical patent/JP2004533421A5/ja
Withdrawn legal-status Critical Current

Links

JP2002574998A 2001-03-27 2002-03-27 T1免疫応答とt2免疫応答との間で調節するためのワクチン Withdrawn JP2004533421A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27869801P 2001-03-27 2001-03-27
PCT/IB2002/002188 WO2002076485A2 (en) 2001-03-27 2002-03-27 Vaccine for modulating between t1 and t2 immune responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010255171A Division JP5519477B2 (ja) 2001-03-27 2010-11-15 T1免疫応答とt2免疫応答との間で調節するためのワクチン

Publications (2)

Publication Number Publication Date
JP2004533421A JP2004533421A (ja) 2004-11-04
JP2004533421A5 true JP2004533421A5 (https=) 2005-12-22

Family

ID=23065998

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002574998A Withdrawn JP2004533421A (ja) 2001-03-27 2002-03-27 T1免疫応答とt2免疫応答との間で調節するためのワクチン
JP2010255171A Expired - Fee Related JP5519477B2 (ja) 2001-03-27 2010-11-15 T1免疫応答とt2免疫応答との間で調節するためのワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010255171A Expired - Fee Related JP5519477B2 (ja) 2001-03-27 2010-11-15 T1免疫応答とt2免疫応答との間で調節するためのワクチン

Country Status (9)

Country Link
US (3) US8198400B2 (https=)
EP (1) EP1377275B1 (https=)
JP (2) JP2004533421A (https=)
AT (1) ATE343375T1 (https=)
AU (1) AU2002309141B2 (https=)
CA (1) CA2441809C (https=)
DE (1) DE60215627T2 (https=)
ES (1) ES2424131T3 (https=)
WO (1) WO2002076485A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004533421A (ja) 2001-03-27 2004-11-04 バイオミラ,インコーポレイテッド T1免疫応答とt2免疫応答との間で調節するためのワクチン
ES2375992T3 (es) * 2002-04-15 2012-03-08 Oncothyreon Inc. Glucolipopéptidos sintéticos como vacunas.
EP1677773A1 (en) * 2003-10-14 2006-07-12 Biomira, Inc. Combination therapy for cancer
TWI395591B (zh) * 2004-04-01 2013-05-11 Oncothyreon Inc 黏液性糖蛋白(muc-1)疫苗
US8871250B2 (en) 2005-06-28 2014-10-28 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
US8703180B1 (en) * 2007-10-23 2014-04-22 Abbott Cardiovascular Systems Inc. Multiple growth factor compositions, methods of fabrication, and methods of treatment
ES2555858T3 (es) * 2009-03-24 2016-01-11 Transgene Sa Biomarcador para el control de pacientes
CN102483405B (zh) 2009-07-10 2015-12-02 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
EP2678005A4 (en) 2011-02-24 2015-06-10 Oncothyreon Inc GLUCOLOPOPEPTIDE MUC1-BASED VACCINE WITH AN ADJUVANS
CA2935511C (en) 2014-01-07 2023-04-04 Babita Agrawal Immunomodulatory compositions comprising heat-killed caulobacter crescentus and methods of use thereof
CN107921113A (zh) 2015-08-25 2018-04-17 巴比塔·阿格拉沃尔 免疫调节组合物及其使用方法
CN110418648B (zh) * 2017-02-22 2023-09-08 丁恩雨 一种编码人GM-CSF与多串连表位融合的mRNA癌症疫苗

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en) 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
ZA831547B (en) 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
DE3683688D1 (de) 1985-04-19 1992-03-12 Wistar Inst Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4868155A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
US5993823A (en) 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
ES2044781B1 (es) 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
WO1993022343A1 (en) * 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AU2247095A (en) 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
WO1995029927A2 (en) 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
AU6260796A (en) 1995-06-07 1996-12-30 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecul es and uses thereof
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JP2001510440A (ja) 1996-03-20 2001-07-31 スローン―ケタリング・インスティテュート・フォー・キャンサー・リサーチ ムチン接合体ペプチドワクチン
WO1997038010A2 (en) * 1996-04-11 1997-10-16 The University Of British Columbia Fusogenic liposomes
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
CA2289742C (en) 1997-05-08 2013-07-16 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) * 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US20020051813A1 (en) 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
ATE290879T1 (de) 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
CA2383737C (en) 1999-09-08 2011-01-18 Transgene S.A. Muc-1 derived peptides
ATE518874T1 (de) 1999-11-15 2011-08-15 Oncothyreon Inc Synthetische lipid-a analogen und verwendungen davon
WO2001070265A2 (en) 2000-03-24 2001-09-27 Biomira, Inc. Lipopeptide adjuvants
EP1182210A1 (en) 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
AU2002219998B2 (en) 2000-12-01 2006-03-02 Biomira, Inc. Preparation of large liposomes by infusion into peg
JP2004533421A (ja) 2001-03-27 2004-11-04 バイオミラ,インコーポレイテッド T1免疫応答とt2免疫応答との間で調節するためのワクチン
ES2375992T3 (es) 2002-04-15 2012-03-08 Oncothyreon Inc. Glucolipopéptidos sintéticos como vacunas.
JP5014573B2 (ja) 2002-05-09 2012-08-29 オンコサイレオン インコーポレーテッド 脂質aおよび他の炭水化物リガンド類似体
TWI395591B (zh) 2004-04-01 2013-05-11 Oncothyreon Inc 黏液性糖蛋白(muc-1)疫苗
US8871250B2 (en) 2005-06-28 2014-10-28 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine

Similar Documents

Publication Publication Date Title
JP2004533421A5 (https=)
Felnerova et al. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs
JP2828391B2 (ja) オリゴ糖を表面に有するリポソーム
AU2002311616B2 (en) A method for preparation of vesicles loaded with biological material and different uses thereof
Arunagirinathan et al. Self-assembled surfactant nano-structures important in drug delivery: a review
RU2311911C2 (ru) Способ усиления иммунного ответа при вакцинации нуклеиновой кислотой
JP2023517644A5 (https=)
EP2040745B1 (en) Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
JP6016970B2 (ja) インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
JP5519477B2 (ja) T1免疫応答とt2免疫応答との間で調節するためのワクチン
US5576017A (en) Heterovesicular liposomes
US20160199440A1 (en) Designed peptides for tight junction barrier modulation
JPH05503521A (ja) 指状突起―融合リポソームおよびゲル
US20050058697A1 (en) Cell penetrating therapeutic agents
AU2002309141A1 (en) Vaccine for modulating between T1 and T2 immune responses
KR20170016315A (ko) 알루미늄 염-흡착 백신의 면역자극 효력의 증진 방법
CA2802443C (en) Vaccine compositions based on sticholysin encapsulated in liposomes
Bally et al. Novel procedures for generating and loading liposomal systems
EP0393145A1 (en) Spontaneous vesiculation of multilamellar liposomes
CA1334165C (en) Affinity associated vaccine
WO2016103273A1 (en) A dna vaccine formulation in cationic liposome vehicle useful for maximizing vaccine potency for leishmaniasis
KR100189701B1 (ko) B형 간염 바이러스의 x 단밸직 유래의 펩타이드 항원을 함유하는 리포좀
Borkar et al. A Concise Review of Liposomal Vaccine Tailoring Methods for Enhancing Vaccination Efficacy
EP1852126A2 (en) Vaccine for modulating between T1 and T2 immune responses
HK1039064B (en) Immunogenic liposome compositions